Currently, 851 medicines are in development for diseases that exclusively or disproportionately affect women, according to a report unveiled today by the Pharmaceutical Research and Manufacturers of America (PhRMA).
Currently, 851 medicines are in development for diseases that exclusively or disproportionately affect women, according to a report unveiled today by the Pharmaceutical Research and Manufacturers of America (PhRMA). The medicines in the pipeline for women (either in human clinical trials or awaiting review by the Food and Drug Administration) include:
• 139 for cancers affecting women, including 91 for breast cancer, 49 for ovarian cancer, and 9 for cervical cancer.
• 114 for arthritis/musculoskeletal disorders. Approximately 46 million Americans have some type of arthritis or related condition, and 60 percent of them are female.
• 64 for obstetric/gynecologic conditions.
• 110 for autoimmune diseases, which strike women three times more than men.
• 72 for depression and anxiety. Almost twice as many women as men suffer from these disorders.
• 83 for Alzheimer’s disease. Two-thirds (3.4 million) of the 5.4 million Americans living with Alzheimer’s today are women.
The Drug Discovery Process
Ovarian cancer affected an estimated 21,880 U.S. women in 2010 and caused an estimated 13,850 deaths. The PhRMA report highlighted a potential first-in-class ovarian cancer drug (volasertib/BI 6727) in development which works by selectively inhibiting the polo-like kinase-1 (PLK-1), an enzyme crucial for cell division. PLK-1 is expressed in proliferating cells and most tumors. Inhibiting its activity disrupts cell division, which induces cell death and reduces cancer growth.
The ovarian cancer drugs listed in the PhRMA report are listed below by name (brand name, if available, and generic name), manufacturer, and phase of clinical testing. The ovarian cancer drugs listed in the “Cancer” section of the PhRMA report are set forth below:
A6, Angstrom Pharmaceuticals, Phase II.
Abagovomab (anti-idiotype ovarian cancer vaccine)(Orphan Drug), Menarini, Phase I/II.
Abraxane®/albumin-bound paclitaxel, Celgene, Phase II.
ABT-888/veliparib, Abbott Laboratories, Phase II.
AE-37, Antigen Express, Phase I.
Afinitor®/everolimus, Novartis Pharmaceuticals, Phase I/II.
AMG 386, Amgen, Phase III.
AMG 479, Amgen, Phase II.
Avastin®, bevacizumab, Genentech, Phase III.
BC-819, BioCancell Therapeutics, Phase I/II.
Catumaxomab, Fresenius Biotech, Phase II.
CVac™/MUC-2 cancer vaccine, Prima BioMed, Phase II.
DCVax®-L/ovarian cancer vaccine, Northwest Biotherapeutics, Phase I.
DPX-0907, Immunovaccine, Phase I.
EC-145, Endocyte, Phase II.
EGEN-001 (Orphan Drug), EGEN, Phase I/II.
ENMD-2076, EntreMed, Phase II.
Estybon™/ON-01910.Na, Onconova Therapeutics, Phase II.
Evizon™/squalamine, OHR Pharmaceuticals, Phase II.
farletuzumab/MORAb-003, Eisai, Phase III.
iboctadekin, GlaxoSmithKline, Phase I.
IMT-1012/immunotherapeutic vaccine, Immunotope, Phase I.
iniparib/BSI-201, BiPar Sciences/sanofi-aventis, Phase II.
Karenitecin®/cositecan, BioNumerik Pharmaceuticals, Phase III.
KHK-2866, Kyowa Hakko Kirin Pharma, Phase I.
lenvatinib/E7080, Eisai, Phase II.
MK-2206, Merck, Phase I.
Nexavar®/sorafenib, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals, Phase II.
NKTR-102, Nektar Therapeutics, Phase II.
NOV-002, Novelos Therapeutics, Phase II.
OGX-427, Oncogenex Pharmaceuticals, Phase I.
olaparib/AZD2281, AstraZeneca, Phase II.
Opaxio™/paclitaxel poliglumex, Cell Therapeutics/Novartis Pharmaceuticals, Phase III.
Optisome™/topetecan liposomal, Talon Therapeutics, Phase I.
Oregovomab, Quest Pharmatech, Phase I/II.
OSI-906/linsitinib, OSI Pharmaceuticals, Phase II.
OVax®/ovarian cancer vaccine (Orphan Drug), AVAX Technologies, Phase I/II.
Perifosine/KRX-0401, AEterna Zentaris/Keryx Biopharmaceuticals, Phase I.
PF-01367338, Pfizer, Phase II.
Phenoxodiol (next generation drug will be NV-143), Marshall Edwards, Phase III.
Picoplatin intravenous, Poniard Pharmaceuticals, Phase II.
Quinamed®/amonafide, ChemGenex Pharmaceuticals, Phase II.
Ramucirumab/IMC-1121-B, Eli Lilly/ImClone, Phase I.
Ridaforolimus, Merck/Ariad Pharmaceuticals, Phase I.
Sagopilone, Bayer HealthCare Pharmaceuticals, Phase II.
SAR256212/MM-121, Merrimack Pharmaceuticals/sanofi-aventis, Phase I.
SG2000, Spirogen, Phase II.
Sprycel®/dasatinib, Bristol-Myers Squibb, Phase
Tarceva®/erlotinib, Genentech, Phase II.
Telcyta®/canfosfimide, Telik, Phase III.
Tigatuzumab, Daiichi Sankyo, Phase II.
Tykerb®/lapatinib, GlaxoSmithKline, Phase I/II.
Volasertib, Boehringer Ingelheim Pharmaceuticals, Phase II.
Volociximab, Bigen Idec/Facet Biotech, Phase II.
Vosaroxin™/SNS-595, Sunesis Pharmaceuticals, Phase II.
Votrient®/pazopanib, GlaxoSmithKline, Phase III.
Zolinza®/vorinostat, Merck, Phase II.
Zybrestat™/fosbretabulin, OXiGENE, Phase II.
1/The 2011 PhRMA report lists 49 ovarian cancer drugs in development. After comparing the entire “Cancer” drug list set forth on pages 16 – 24 of the PhRMA report to the ovarian cancer clinical trials provided at http://www.clinicaltrials.gov, we determined that an additional nine drugs appearing on the PhRMA cancer drug list are being tested in ovarian cancer clinical trials.
2/Please note that the PhRMA cancer drug list does not set forth all ovarian cancer drugs in development. For a list of all open ovarian cancer clinical trials listed at www.clinicaltrials.gov, click here.